Extrait

After 26 weeks, in subjects with T2DM and inadequate glycemic control on treatment with metformin ≥1500 mg/day and sitagliptin 100 mg q.d.: 1) To assess the A1C-lowering efficacy of the addition of ertugliflozin 15 mg q.d. relative to the addition of placebo. 2) To assess the A1C-lowering efficacy of the addition of ertugliflozin 5 mg q.d. relative to the addition of placebo. 3) To assess the safety and tolerability of the addition of ertugliflozin.

Critère d'inclusion

• Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin and sitagliptin

Liens

• euctr
• euctr
• ictrp
• ictrp
• ictrp
• ictrp
• euctr
• ictrp
• euctr
• euctr